Cardiovascular disease in end stage renal disease

Minerva Urologica e Nefrologica

Volumn 58, Issue 2, 2006, Pages 117-131

  Sharma, R ^a   Pellerin, D ^b   Brecker, S J D ^c  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular diseases; Coronary artery disease; End stage renal disease; Kidney transplantation; Mortality; Uremia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TACROLIMUS; THIAZIDE DIURETIC AGENT;

ANEMIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; HEART MUSCLE METABOLISM; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY GRAFT; MICROANGIOPATHY; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERICARDITIS; PREVALENCE; REVIEW; RISK FACTOR; SMOKING;

CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; RISK FACTORS; UREMIA;

EID: 33745482348     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. Raine AE, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant. 1992;7 Suppl 2:7-35.
2. USRDS 2000 Annual data report. 2000.p.583-689.
3. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease: major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995;60:451-7.
4. Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol 2000;20:176-87.
5. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57:307-13.
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-9.
7. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-52.
8. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001;161:886-91.
9. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000;11:1735-43.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
11. Erratum in: JAMA 2003;290:197.
12. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998;54:561-9.
13. Erratum in: Kidney Int 1998;54:1417.
14. Incidence and prevalence of ESRD. United States Renal Data System. Am J Kidney Dis 1998;32:S38-49.
15. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979;59:8-13.
16. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
17. Ford ES, DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Am J Epidemiol 1991;133:1220-30.
18. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 2002;105:1727-33.
19. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia 1978;14:363-70.
20. Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000;70:SS58-63.
21. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996;27:84-91.
22. Aakhus S, Dahl K, Wideroe TE. Hyperlipidaemia in renal transplant patients. J Intern Med 1996;239:407-15.
23. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
24. Silberberg JS, Rahal DP, Patton DR, Sniderman AD. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 1989;64:222-4.
25. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-911.
26. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92.
27. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996;7:728-36.
28. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998;97:138-41.
29. Erratum in: Circulation 1998;97:711.
30. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000;11:134-7.
31. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a metaanalysis. BMJ 2002;325:1202.
32. London GM, Marchais SJ, Guerin AP, Metivier F. Contributive factors to cardiovascular hypertrophy in renal failure. Am J Hypertens 1989;2:261S-263S.
33. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-92.
34. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-90.
35. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-90.
36. Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996;50:1321-6.
37. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998;54:1720-5.
38. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996;11:1277-85.
39. Amann K, Ritz E. Cardiac structure and function in renal disease. Curr Opin Nephrol Hypertens 1996;5:102-6.
40. Stewart GA, Foster J, Cowan M, Rooney E, McDonagh T, Dargie HJ et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999;56:2248-53.
41. Morris ST, Galiatsou E, Stewart GA, Rodger RS, Jardine AG. QT dispersion before and after hemodialysis. J Am Soc Nephrol 1999;10:160-3.
42. London GM, Guerin AP, Marchais SJ. Pathophysiology of left ventricular hypertrophy in dialysis patients. Blood Purif 1994;12:277-83.
43. Himelman RB, Landzberg JS, Simonson JS, Amend W, Bouchard A, Merz R et al. Cardiac consequences of renal transplantation: changes in left ventricular morphology and function. J Am Coll Cardiol 1988;12:915-23.
44. Wizemann V, Blank S, Kramer W. Diastolic dysfunction of the left ventricle in dialysis patients. Contrib Nephrol 1994;106:106-9.
45. Ritz E, Koch M. Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis 1993;21:113-8.
46. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 1987;31:973-80.
47. Hung J, Harris PJ, Uren RF, Tiller DJ, Kelly DT. Uremic cardiomyopathy: effect of hemodialysis on left ventricular function in end-stage renal failure. N Engl J Med 1980;302:547-51.
48. Orth SR, Amann K, Strojek K, Ritz E. Sympathetic over-activity and arterial hypertension in renal failure. Nephrol Dial Transplant 2001;16:67-9.
49. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverse GB. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993;44:881-6.
50. Roithinger FX, Punzengruber C, Wallner M, Ulbrich W, Pachinger O, Kramar R et al. The influence of ACE-inhibition on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure. Clin Nephrol 1994;42:309-14.
51. Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 1992;124:424-7.
52. Fellner SK, Lang RM, Neumann A, Korcarz C, Borow KM. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 1993;44:1309-15.
53. Rigatto C, Foley RN, Kent GM, Guttmann R, Parfrey PS. Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 2000;70:570-5.
54. McGregor E, Jardine AG, Murray LS, Dargie HJ, Rodger RS, Junor BJ et al. Preoperative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant 1998;13:1499-505.
55. Weinrauch LA, D'Elia JA, Monaco AP, Gleason RE, Welty F, Nishan PC et al. Preoperative evaluation for diabetic renal transplantation: impact of clinical, laboratory, and echocardiographic parameters on patient and allograft survival. Am J Med 1992;93:19-28.
56. Bergler-Klein J, Pirich C, Laufer G, Grimm M, Regele H, Mayer G et al. The long-term effect of simultaneous heart and kidney transplantation on native renal function. Transplantation 2001;71:1597-600.
57. Huting J. Progression of valvular sclerosis in end-stage renal disease treated by long-term peritoneal dialysis. Clin Cardiol 1992;15:745-50.
58. Rostand SG, Sanders C, Kirk KA, Rutsky EA, Fraser RG. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 1988;85:651-7.
59. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14:159-68.
60. Fox CS, Larson MG, Vasan RS, Guo CY, Parise H, Levy D et al. Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol 2006;17:521-7.
61. Patient mortality and survival. United States Renal Data System. Am J Kidney Dis 1998;32(2 Suppl 1):S69-80.
62. Braun WE, Marwick TH. Coronary artery disease in renal transplant recipients. Cleve Clin J Med 1994;61:370-85.
63. Pidgeon GB, Lynn KL, Bailey RR, Robson RA. Coronary angiography prior to renal transplantation. Nephrology 1995;1:59-64.
64. Manske CL, Thomas W, Wang Y, Wilson RF. Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup. Kidney Int 1993;44:617-21.
65. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
66. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-23.
67. Gruberg L, Rai P, Mintz GS, Canos D, Pinnow E, Satler LF et al. Impact of renal function on coronary plaque morphology and morphometry in patients with chronic renal insufficiency as determined by intravascular ultrasound volumetric analysis. Am J Cardiol 2005;96:892-6.
68. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002;106:100-5.
69. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
70. Gradaus F, Ivens K, Peters AJ, Heering P, Schoebel FC, Grabensee B et al. Angiographic progression of coronary artery disease in patients with end-stage renal disease. Nephrol Dial Transplant 2001;16:1198-202.
71. Wheeler DC. Ischaemic heart disease after renal transplantation: how to assess and minimize the risk. Nephrol Dial Transplant 1999;14:1075-7.
72. Rostand SG, Kirk KA, Rutsky EA. The epidemiology of coronary artery disease in patients on maintenance hemodialysis: implications for management. Contrib Nephrol 1986;52:34-41.
73. Abe S, Yoshizawa M, Nakanishi N, Yazawa T, Yokota K, Honda M et al. Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J 1996;131:1137-44.
74. Wizemann V. Coronary artery disease in dialysis patients. Nephron 1996;74:642-51.
75. Schmidt A, Stefenelli T, Schuster E, Mayer G. Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis 2001;37:56-63.
76. Holley JL, Fenton RA, Arthur RS. Thallium stress testing does not predict cardiovascular risk in diabetic patients with end-stage renal disease undergoing cadaveric renal transplantation. Am J Med 1991;90:563-70.
77. Marwick TH, Cain P. Screening for coronary artery disease. Med Clin North Am 1999;83:1375-402, v-vi.
78. Reis G, Marcovitz PA, Leichtman AB, Merion RM, Fay WP, Werns SW et al. Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. Am J Cardiol 1995;75:707-10.
79. Herzog CA, Marwick TH, Pheley AM, White CW, Rao VK, Dick CD. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. Am J Kidney Dis 1999;33:1080-90.
80. Sharma R, Pellerin D, Gaze DC, Shah JS, Streather CP, Collinson PO et al. Dobutamine stress echocardiography and cardiac troponin T for the detection of significant coronary artery disease and predicting outcome in renal transplant candidates. Eur J Echocardiogr 2005;6:327-35.
81. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143-9.
82. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-36.
83. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598-603.
84. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-9.
85. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9:1018-22.
86. Orth SR, Viedt C, Amann K, Ritz E. Endothelin in renal diseases and cardiovascular remodeling in renal failure. Intern Med 2001;40:285-91.
87. Beaubien ER, Pylypchuk GB, Akhtar J, Biem HJ. Value of corrected QT interval dispersion in identifying patients initiating dialysis at increased risk of total and cardiovascular mortality. Am J Kidney Dis 2002;39:834-42.
88. Raizada V, Skipper B, Luo W, Garza L, Hines CW, Harford AA et al. Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease. Kidney Int 2005;68:1186-9.
89. Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000;140:886-90.
90. Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005;46:897-902.
91. Sforzini S, Latini R, Mingardi G, Vincenti A, Redaelli B. Ventricular arrhythmias and four-year mortality in haemodialysis patients. Gruppo Emodialisi e Patologie Cardiovascolari. Lancet 1992;339:212-3.
92. Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005;68:818-25.
93. Sharples EJ, Pereira D, Summers S, Cunningham J, Rubens M, Goldsmith D et al. Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am J Kidney Dis 2004;43:313-9.
94. Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M, Goldsmith DJ. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant 2004;19:2307-12.
95. Chhabra SC, Puri S, Wander GS, Shahi RG. Mitral annular calcification in untreated chronic renal failure. J Assoc Physicians India 1992;40:91-4.
96. Matthias S, Ritz E, Waldherr R. [Therapy of glomerulonephritis]. Internist (Berl) 1995;36:218-26.
97. Raine AE, Seymour AM, Roberts AF, Radda GK, Ledingham JG. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993;92:2934-40.
98. Beretta-Piccoli C, Weidmann P, Schiffl H, Cottier C, Reubi FC. Enhanced cardiovascular pressor reactivity to norepinephrine in mild renal parenchymal disease. Kidney Int 1982;22:297-303.
99. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 1996;7:667-75.
100. Stolear JC, Georges B, Shita A, Verbeelen D. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. Nephrol Dial Transplant 1999;14:1961-7.
101. Frankel WL, Herold DA, Ziegler TW, Fitzgerald RL. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol 1996;106:118-23.
102. Collinson PO, Hadcocks L, Foo Y, Rosalki SB, Stubbs PJ, Morgan SH et al. Cardiac troponins in patients with renal dysfunction. Ann Clin Biochem 1998;35(Pt 3):380-6.
103. Mockel M, Schindler R, Knorr L, Muller C, Heller G Jr, Stork TV et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. Nephrol Dial Transplant 1999;14:1489-95.
104. Ooi DS, House AA. Cardiac troponin T in hemodialyzed patients. Clin Chem 1998;44:1410-6.
105. Lowbeer C, Ottosson-Seeberger A, Gustafsson SA, Norrman R, Hulting J, Gutierrez A. Increased cardiac troponin T and endothelin-1 concentrations in dialysis patients may indicate heart disease. Nephrol Dial Transplant 1999;14:1948-55.
106. Ooi DS, Zimmerman D, Graham J, Wells GA. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem 2001;47:412-7.
107. Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000;102:1964-9.
108. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002;106:2941-5.
109. Jeon DS, Lee MY, Kim CJ, Cho JM, Moon KW, Kim BS et al. Clinical findings in patients with cardiac troponin T elevation and end-stage renal disease without acute coronary syndrome. Am J Cardiol 2004;94:831-4.
110. Sharma R, Gaze DC, Pellerin D, Metha R, Gregson H, Streather CP et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart 2005; [Epub ahead of print].
111. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003;290:353-9.
112. Porter GA, Norton TL, Lindsley J, Stevens JS, Phillips DS, Bennett WM. Relationship between elevated serum troponin values in end-stage renal disease patients and abnormal isotopic cardiac scans following stress. Ren Fail 2003;25:55-65.
113. Obialo CI, Sharda S, Goyal S, Ofili EO, Oduwole A, Gray N. Ability of troponin T to predict angiographic coronary artery disease in patients with chronic kidney disease. Am J Cardiol 2004;94:834-6.
114. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003;42:201-8.
115. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
116. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
117. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
118. Erratum in: Ann Intern Med 2002;137:299.
119. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
120. Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992;62:161-5.
121. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9.
122. Schoebel FC, Gradaus F, Ivens K, Heering P, Jax TW, Grabensee B et al. Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography. Heart 1997;78:337-42.
123. Le Feuvre C, Dambrin G, Helft G, Beygui F, Touam M, Grunfeld JP et al. Clinical outcome following coronary angioplasty in dialysis patients: a case-control study in the era of coronary stenting. Heart 2001;85:556-60.
124. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-9.
125. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769-75.
126. Rinehart AL, Herzog CA, Collins AJ, Flack JM, Ma JZ, Opsahl JA. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 1995;25:281-90.
127. Nakayama Y, Sakata R, Ura M, Miyamoto TA. Coronary artery bypass grafting in dialysis patients. Ann Thorac Surg 1999;68:1257-61.
128. Franga DL, Kratz JM, Crumbley AJ, Zellner JL, Stroud MR, Crawford FA. Early and long-term results of coronary artery bypass grafting in dialysis patients. Ann Thorac Surg 2000;70:813-8; discussion 819.
129. Dacey LJ, Liu JY, Braxton JH, Weintraub RM, DeSimone J, Charlesworth DC et al.; Northern New England Cardiovascular Disease Study Group. Long-term survival of dialysis patients after coronary bypass grafting. Ann Thorac Surg 2002;74:458-62; discussion 462-3.
130. Ferguson ER, Hudson SL, Diethelm AG, Pacifico AD, Dean LS, Holman WL. Outcome after myocardial revascularization and renal transplantation: a 25-year single-institution experience. Ann Surg 1999;230:232-41.
131. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. Circulation 2004;109:2866-71.
132. Agirbasli M, Weintraub WS, Chang GL, King SB, Guyton RA, Thompson TD et al. Outcome of coronary revascularization in patients on renal dialysis. Am J Cardiol 2000;86:395-9.
133. Dimeny EM. Cardiovascular disease after renal transplantation. Kidney Int Suppl 2002:78-84.
134. Kasiske BL, Ramos EL, Gaston RS, Bia MJ, Danovitch GM, Bowen PA et al. The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1995;6:1-34.
135. European Best Practice Guidelines for Renal Transplantation (Part 1). Nephrol Dial Transplant 2000;15 Suppl 7:1-85.
136. Manske CL, Wang Y, Rector T, Wilson RF, White CW. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992;340:998-1002.
137. Armstrong KA, Rakhit DJ, Case C, Johnson DW, Isbel NM, Marwick TH. Derivation and validation of a disease-specific risk score for cardiac risk stratification in chronic kidney disease. Nephrol Dial Transplant 2005;20:2097-104.
138. Sharma R, Pellerin D, Gaze DC, Mehta RL, Gregson H, Streather CP et al. Dynamic left ventricular obstruction: A potential cause of angina in end stage renal disease (IJCA-g-0979). Int J Cardiol 2005; [Epub ahead of print].
139. Sharma R, Pellerin D, Gaze DC, Gregson H, Streather CP, Collinson PO et al. Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates. Nephrol Dial Transplant 2005;20:2207-14.
140. Patel AD, Abo-Auda WS, Davis JM, Zoghbi GJ, Deierhoi MH, Heo J et al. Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation. Am J Cardiol 2003;92:146-51.
141. Erratum in: Am J Cardiol 2004;93:129-30.
142. Dahan M, Viron BM, Poiseau E, Kolta AM, Aubry N, Paillole C et al. Combined dipyridamole-exercise stress echocardiography for detection of myocardial ischemia in hemodialysis patients: an alternative to stress nuclear imaging. Am J Kidney Dis 2002;40:737-44.
143. Picano E, Lattanzi F, Orlandini A, Marini C, L'Abbate A. Stress echocardiography and the human factor: the importance of being expert. J Am Coll Cardiol 1991;17:666-9.
144. Fathi R, Cain P, Nakatani S, Yu HC, Marwick TH. Effect of tissue Doppler on the accuracy of novice and expert interpreters of dobutamine echocardiography. Am J Cardiol 2001;88:400-5.
145. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-7.
146. Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic Peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004;50:2279-85.
147. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006;47:493-502.
148. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev 2003;8:355-8.